Pancreatic Cancer Research

Clinical trialObsWithdrawn

Observational Study of ctDNA in Resectable and Borderline Resectable Pancreatic Cancer

NCT05379907↗ ClinicalTrials.gov, retrieved 4 November 2026

Outcome
Stopped earlyDetermined that the tumor analysis could not be performed in accordance with the protocol. (Other)
Phase
Obs
Status
Withdrawn
Study type
Observational
Start
23 August 2022
Expected end
23 August 2023
Enrollment
0 participants
Sites
1
Primary outcomes
Impact of SIGNATERA™ on treatment decisions
Sponsor
Other
Results posted
No
Last update
6 September 2023

These are registry fields. A trial card, with population, design, endpoints and result direction each tied to a quote, is not in the data yet.

Ask this document

Answers come only from this document’s own text, as highlighted quotes. If it doesn’t say, you are told so instead of given a guess. Only its metadata is loaded so far, so most questions will be declined.

Try

Papers 5